TP53 and neoplasm: Based on the different subgroups of clinical patients, it was shown that high LINC01589 expression correlated with a longer OS in stage II to IV groups (HR = 0.40, 95% CI [0.23–0.71], P = .002) as well as in the endometroid type of UCEC groups (HR = 0.42, 95% CI [0.23–0.76], P = .004), complete recovery groups (HR = 0.34, 95% CI [0.19–0.62], P < .001), in the lower tumor invasion groups (HR = 0.41, 95% CI [0.18–0.92], P = .031), and the TP53 mutation groups (HR = 0.40, 95% CI [0.21–0.75], P = .005).